骨保护素与缺血性卒中预后:一项前瞻性多中心研究及孟德尔随机化分析
该前瞻性多中心研究纳入中国26家医院2009年8月至2013年5月招募的3490例缺血性卒中患者,检测基线血浆骨保护素水平,主要结局为卒中后3个月死亡和重大残疾的复合结局。校正年龄、性别、入院美国国立卫生研究院卒中量表评分等协变量后,骨保护素升高与主要结局风险增加相关(比值比1.40,95%CI 1.05-1.88),孟德尔随机化分析显示遗传决定的高血浆骨保护素与主要结局风险增加相关(比值比5.74,95%CI 1.12-29.44,P=0.036)。
要点
- 校正混杂因素后,骨保护素最高与最低四分位组比较,主要结局比值比1.40(95%CI 1.05-1.88)。
- log-骨保护素每升高1个标准差,主要结局风险增加18%(95%CI 6%-32%)。
- 孟德尔随机化分析中遗传决定的高骨保护素与主要结局风险增加相关(比值比5.74,95%CI 1.12-29.44)。
核心结论
- 血浆骨保护素升高与缺血性卒中不良预后相关,孟德尔随机化分析显示遗传决定的高血浆骨保护素与主要结局风险增加相关。
研究设计与样本
- 前瞻性多中心研究,遵循STROBE报告规范,纳入中国26家医院2009年8月至2013年5月招募的3490例缺血性卒中患者,检测基线血浆骨保护素水平,并结合孟德尔随机化分析。
主要发现
- 校正年龄、性别、入院美国国立卫生研究院卒中量表评分及其他重要协变量后,比较骨保护素最高与最低两个极端四分位组,骨保护素升高与主要结局风险增加相关(比值比1.40,95%CI 1.05-1.88)、死亡风险增加相关(风险比2.05,95%CI 1.04-4.08)、死亡和血管事件复合结局风险增加相关(风险比2.00,95%CI 1.15-3.48)。
- log-骨保护素每升高1个标准差,主要结局风险增加18%(95%CI 6%-32%),死亡风险增加69%(95%CI 31%-118%),死亡和血管事件复合结局风险增加53%(95%CI 24%-89%)。
- 多因素校正样条回归模型显示骨保护素与主要结局呈线性关联(线性检验P<0.001)。
- 将骨保护素加入传统危险因素未显著改善区分度(C统计量0.817 vs 0.818,P=0.232),但轻度改善主要结局的风险重分类(净重分类改善13.68%,P<0.001;综合判别改善0.23%,P=0.039)。
- 孟德尔随机化分析中,遗传决定的高血浆骨保护素与主要结局风险增加相关(比值比5.74,95%CI 1.12-29.44,P=0.036)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoprotegerin was implicated in vascular injury and inflammatory responses, but its prognostic value in ischemic stroke remained unclear. We aimed to prospectively investigate the association between plasma osteoprotegerin and ischemic stroke prognosis combined with a Mendelian randomization analysis. METHODS: Our prospective study follows the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guideline. We measured baseline plasma osteoprotegerin levels for 3490 ischemic stroke patients recruited between August 2009 and May 2013 in 26 hospitals across China. The primary outcome was a composite outcome of death and major disability at 3 months after ischemic stroke. RESULTS: After adjustment for age, sex, admission National Institutes of Health Stroke Scale score, and other important covariates, elevated osteoprotegerin levels were associated with increased risks of primary outcome (odds ratio, 1.40 [95% CI, 1.05-1.88]), death (hazard ratio, 2.05 [95% CI, 1.04-4.08]), and composite outcome of death and vascular events (hazard ratio, 2.00 [95% CI, 1.15-3.48]) when 2 extreme quartiles were compared. Each 1-SD higher log-osteoprotegerin was associated with a 18% (95% CI, 6%-32%) increased risk of primary outcome, 69% (95% CI, 31%-118%) increased risk of death, and 53% (95% CI, 24%-89%) increased risk of composite outcome of death and vascular events, respectively. Multiple-adjusted spline regression model showed a linear association of osteoprotegerin with primary outcome (P for linearity <0.001). Adding osteoprotegerin to conventional risk factors did not significantly improve discriminatory power (C statistics, 0.817 versus 0.818; P=0.232) but did slightly improve the risk reclassification of primary outcome (net reclassification improvement: 13.68%, P<0.001; integrated discrimination improvement: 0.23%, P=0.039). In Mendelian randomization analysis, genetically determined high plasma osteoprotegerin was associated with increased risk of primary outcome (odds ratio, 5.74 [95% CI, 1.12-29.44]; P=0.036). CONCLUSIONS: Elevated plasma osteoprotegerin was associated with poor prognosis of ischemic stroke, and genetically determined high plasma osteoprotegerin was associated with an increased risk of primary outcome in Mendelian randomization analysis. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01840072.
引用
- Zhu Z, Guo D, Zhang K, et al. Osteoprotegerin and Ischemic Stroke Prognosis: A Prospective Multicenter Study and Mendelian Randomization Analysis. Stroke. 2022. PMID: 36511149. doi:10.1161/STROKEAHA.122.040800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。